Ryan Scott
Assistant Editor at OncLive
Assistant editor for @onclive. All tweets and thoughts are my own.
Articles
-
2 weeks ago |
curetoday.com | Ryan Scott
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type of brain cancer.
-
2 months ago |
oncnursingnews.com | Ryan Scott
Men with intermediate-risk prostate cancer and high prostate-specific antigen (PSA) levels before high-intensity focused ultrasound (HIFU) treatment faced a greater risk of recurrence and treatment failure, according to research presented at the 2025 ASCO Genitourinary Cancers Symposium. In this investigation of 108 men with intermediate-risk prostate cancer following HIFU, investigators found that in-field and overall recurrence on 1-year biopsy was 41% and 54%, respectively.
-
2 months ago |
targetedonc.com | Ryan Scott
Research presented in a poster at the 2025 ASCO Genitourinary Cancers Symposium found that high prostate-specific antigen (PSA) levels before High-Intensity Focused Ultrasound (HIFU) were associated with a greater risk of overall recurrence and treatment failure in patients with intermediate-risk prostate cancer.
-
2 months ago |
targetedonc.com | Ryan Scott
Data from a phase 3 clinical trial (CTR20190050), presented at the 2025 Gastrointestinal Cancers Symposium, demonstrated that the oral solution of paclitaxel (Liporaxel) was non-inferior to the intravenous (IV) solution in progression-free survival (PFS) for second-line advanced gastric cancer. However, oral paclitaxel showed superior overall survival (OS) compared with the IV formulation.
-
2 months ago |
onclive.com | Ryan Scott
The combination of bezuclastinib (CGT9486) and sunitinib (Sutent) generated favorable efficacy outcomes compared with historical data, as well as long-term tolerability, in patients with previously treated gastrointestinal stromal tumors (GIST), according to findings from part 1 of the phase 3 Peak study (NCT05208047) that were presented at the 2025 Gastrointestinal Cancers Symposium.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 62
- Tweets
- 22
- DMs Open
- No
In this episode of #OncLiveOnAir, Dr @garciamanero, of @MDAndersonNews, discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress. #MedEd #Hematology https://t.co/XYXKhrDdCr https://t.co/o1iqAvGnSo
Hear updates from the experts themselves on #OncLiveOnAir. This week, tune in to hear from Dr @DrRaviSalgia, of @cityofhope, as he shares how he chooses b/w tepotinib & capmatinib in pts w/ stage IV NSCLC harboring MET exon 14 skipping mutations. #lcsm https://t.co/pEXFbofrlN https://t.co/jtsBl9ngYh
❗ ICYMI: NXP800 was granted orphan drug designation by the @US_FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.💡 Read more from @OncLive here: https://t.co/7VFKAa08bp
